BeStock  
Stocks › Biotechnology › RARE

Ultragenyx Pharmaceutical RARE

US equityMarket cap rank #2801Biotechnology
$16.48 −$0.74 (-4.30%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $16.50 +0.12%
Open$16.94
Prev close$17.22
Day range$16.43 – $17.35
Volume3.01M
Market cap$1.68B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$173.00M+8.1% YoY
Operating profit-$110.00M+35.7% YoY
Net profit-$118.00M+34.4% YoY
Diluted EPS-$1.16+35.9% YoY
Free cash flow-$45.00M+51.1% YoY
Operating cash flow-$43.00M

Revenue, last 8 quarters

$164.6MDec '24$139.0MMar '25$167.0MJun '25$160.0MSep '25$207.0MDec '25$136.0MMar '26$214.0MJun '26$173.0MSep '26

Net profit, last 8 quarters

$-133.2MDec '24$-151.0MMar '25$-115.0MJun '25$-180.0MSep '25$-129.0MDec '25$-185.0MMar '26$-92.0MJun '26$-118.0MSep '26

Diluted EPS by quarter

-1.39Dec '24-1.57Mar '25-1.17Jun '25-1.81Sep '25-1.29Dec '25-1.84Mar '26-0.90Jun '26-1.16Sep '26

Free cash flow by quarter

$-80.0MDec '24$-182.0MMar '25$-112.0MJun '25$-92.0MSep '25$-101.0MDec '25$-203.0MMar '26$-98.0MJun '26$-45.0MSep '26

Annual revenue

$271.0MFY20$351.4MFY21$363.3MFY22$434.0MFY23$560.0MFY24$673.0MFY25

Profitability & balance sheet

Gross margin82.9%
Operating margin-64.0%
Net margin-71.8%
Return on assets-44.1%
Current ratio1.40
Liabilities / assets131.1%
Cash & investments$266.00M
Net cash (debt)$266.00M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $173.00M $214.00M $136.00M $673.00M $207.00M
Total Operating Revenue $173.00M $214.00M $136.00M $673.00M $207.00M
Cost of Revenue $32.00M $34.00M $30.00M $109.00M $29.00M
Gross Profit $141.00M $180.00M $106.00M $564.00M $178.00M
Operating Expense $251.00M $255.00M $275.00M $1.10B $291.00M
Selling and Admin Expenses $97.00M $88.00M $88.00M $349.00M $88.00M
Research & Development $154.00M $167.00M $187.00M $750.00M $203.00M
Operating Profit -$110.00M -$75.00M -$169.00M -$535.00M -$113.00M
Net Non-Operating Interest Income (Expense) -$17.00M -$17.00M -$15.00M -$37.00M -$14.00M
Non-Operating Interest Income $3.00M $5.00M $6.00M $25.00M $6.00M
Non-Operating Interest Expense $20.00M $22.00M $21.00M $62.00M $20.00M
Pretax Profit -$127.00M -$91.00M -$184.00M -$571.00M -$128.00M
Tax -$9.00M $1.00M $1.00M $4.00M $1.00M
Net Profit -$118.00M -$92.00M -$185.00M -$575.00M -$129.00M
Profit from Continuing Operations -$118.00M -$92.00M -$185.00M -$575.00M -$129.00M
Net Income to Parent Company -$118.00M -$92.00M -$185.00M -$575.00M -$129.00M
Net Income to Common Stockholders -$118.00M -$92.00M -$185.00M -$575.00M -$129.00M
Basic EPS -$1.16 -$0.90 -$1.84 -$5.83 -$1.29
Diluted EPS -$1.16 -$0.90 -$1.84 -$5.83 -$1.29
Other Income (Expense) – $1.00M – $1.00M -$1.00M
Other Non-Operating Income (Expenses) – $1.00M – $1.00M -$1.00M

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.19B $1.26B $1.30B $1.53B $1.53B
Total Current Assets $544.00M $606.00M $657.00M $951.00M $951.00M
Cash and Cash Equivalents & Short-Term Investments $266.00M $292.00M $413.00M $680.00M $680.00M
-Cash and Cash Equivalents $150.00M $125.00M $175.00M $421.00M $421.00M
-Short Term Investments $116.00M $167.00M $238.00M $259.00M $259.00M
Receivables $166.00M $200.00M $121.00M $158.00M $158.00M
-Accounts Receivable $166.00M $200.00M $121.00M $158.00M $158.00M
Inventory $59.00M $59.00M $55.00M $52.00M $52.00M
Other Current Assets $53.00M $55.00M $68.00M $61.00M $61.00M
Total Non-Current Assets $643.00M $658.00M $639.00M $581.00M $581.00M
Net PPE $231.00M $235.00M $239.00M $244.00M $244.00M
Investments and Advances $135.00M $144.00M $121.00M $57.00M $57.00M
-Available for Sale Securities $135.00M $144.00M $121.00M $57.00M $57.00M
Goodwill and Other Intangible Assets $214.00M $216.00M $218.00M $220.00M $220.00M
-Goodwill $44.00M $44.00M $44.00M $44.00M $44.00M
-Other Intangible Assets $170.00M $172.00M $174.00M $176.00M $176.00M
Other Non-Current Assets $63.00M $63.00M $61.00M $60.00M $60.00M
Total Liabilities $1.56B $1.55B $1.53B $1.61B $1.61B
Total Current Liabilities $389.00M $351.00M $325.00M $384.00M $384.00M
Payables $45.00M $39.00M $42.00M $31.00M $31.00M
-Accounts Payable $45.00M $39.00M $42.00M $31.00M $31.00M
Current Accrued Expenses $162.00M $149.00M $133.00M $208.00M $208.00M
Current Provisions $80.00M $72.00M $61.00M $57.00M $57.00M
Other Current Liabilities $102.00M $91.00M $89.00M $76.00M $76.00M
Total Non-Current Liabilities $1.17B $1.20B $1.20B $1.22B $1.22B
Non-Current Deferred Liabilities $21.00M $30.00M $30.00M $30.00M $30.00M
Other Non-Current Liabilities $40.00M $41.00M $42.00M $20.00M $20.00M
Total Equity -$369.00M -$284.00M -$229.00M -$73.00M -$73.00M
Stockholders' Equity -$376.00M -$291.00M -$236.00M -$80.00M -$80.00M
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $4.55B $4.52B $4.48B $4.45B $4.45B
Retained Earnings -$4.93B -$4.81B -$4.72B -$4.53B -$4.53B
Less: Treasury Stock -$10.00M -$10.00M -$10.00M -$8.00M -$8.00M
Gains/Losses Not Affecting Retained Earnings -$1.00M $0.00 $0.00 $1.00M $1.00M
Other Equity Interests $10.00M $10.00M $10.00M $8.00M $8.00M
Minority Interests $7.00M $7.00M $7.00M $7.00M $7.00M
-Gross PPE – – – $380.00M $380.00M
-Accumulated Depreciation – – – -$136.00M -$136.00M
Short-Term Debt and Capital Lease Obligation – – – $12.00M $12.00M
-Current Capital Lease Obligation – – – $12.00M $12.00M
Long Term Debt and Capital Lease Obligation – – – $24.00M $24.00M
-Long Term Capital Lease Obligation – – – $24.00M $24.00M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$43.00M -$97.00M -$197.00M -$466.00M -$100.00M
Net cash flow from continuing operations -$43.00M -$97.00M -$197.00M -$466.00M -$100.00M
Net Income from Continuing Operations -$118.00M -$92.00M -$185.00M -$575.00M -$129.00M
Depreciation & Depletion & Amortization $9.00M $8.00M $8.00M $35.00M $9.00M
Other Non-Cash Items -$4.00M -$18.00M $2.00M -$52.00M -$17.00M
Change in Working Capital $46.00M -$29.00M -$51.00M -$23.00M $0.00
-Change in Receivables $23.00M -$62.00M $19.00M -$31.00M -$34.00M
-Change in Inventory -$1.00M -$3.00M -$4.00M -$6.00M $0.00
-Change in Prepaid Assets -$1.00M $12.00M -$9.00M -$10.00M -$3.00M
-Change in Payables and Accrued Expense $25.00M $24.00M -$57.00M $24.00M $37.00M
Net cash flow from investing $58.00M $44.00M -$49.00M $236.00M -$72.00M
Net Cash Flow from Continuing Investing Activities $58.00M $44.00M -$49.00M $236.00M -$72.00M
Net PPE Purchase and Sale -$2.00M -$1.00M -$1.00M -$6.00M -$1.00M
Net Intangibles Purchase and Sale $0.00 $0.00 -$5.00M -$15.00M $0.00
Net Investment Purchase and Sale $59.00M $48.00M -$43.00M $258.00M -$72.00M
Net Other Investing Changes $1.00M – – -$1.00M $1.00M
Financing Cash Flow $10.00M – – $478.00M $394.00M
Net Cash Flow from Continuing Financing Activities $10.00M – – $478.00M $394.00M
Net Common Stock Issuance $10.00M – – $86.00M $2.00M
Ending Cash Balance $164.00M $140.00M $189.00M $436.00M $436.00M
Net Change in Cash $25.00M -$50.00M -$246.00M $248.00M $222.00M
Beginning Cash Balance $140.00M $189.00M $436.00M $184.00M $215.00M
Effect of Exchange Rate Changes -$1.00M $1.00M -$1.00M $4.00M -$1.00M
Free Cash Flow -$45.00M -$98.00M -$203.00M -$487.00M -$101.00M
Net Other Financing Charges – – – $392.00M –

Discussion

No comments yet — be the first to weigh in on RARE.

Sign in to join the discussion.

Scroll to Top